Primary aldosteronism: an update on screening, diagnosis and treatment
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Primary aldosteronism is much more common than previously held; it implies an excessive organ damage to the heart, vessels and kidney, which translates into an excess of cardiovascular events. These two features, along with the fact that the arterial hypertension and the hypokalemia can be corrected with a timely diagnosis and an appropriate therapy, warrant an aggressive diagnostic approach in hypertensive patients. OBJECTIVES: To provide updated information on the screening and exclusion tests for primary aldosteronism and to illustrate the strategy that can be followed for primary aldosteronism subtype differentiation. DESIGN: Review of the literature and personal experience of the authors. RESULTS: The available evidence showed that a cost-effective strategy for the screening of patients with primary aldosteronism can be exploited at most centres. At variance, the identification of primary aldosteronism subtypes, for example, the differentiation of patients with an aldosterone-producing adenoma from those with idiopathic hyperaldosteronism should be undertaken at tertiary referral centres. CONCLUSION: The identification of a curable form of primary aldosteronism can be much rewarding for the patient and the doctor. Thus, an aggressive diagnostic approach is mandatory at least in some subgroups of hypertensive patients who are at higher prior risk of primary aldosteronism or can benefit more from an accurate diagnosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated
Funder, J. W., Pearce, P. T., Smith, R., & Smith, A. I. (1988) · Science · doi:10.1126/science.2845584 · Cited by 1,628
A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients
Rossi, G. P., Bernini, G., Caliumi, C., Desideri, G., Fabris, B., Ferri, C., Ganzaroli, C., Giacchetti, G., Letizia, C., Maccario, M., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.059 · Cited by 1,467
Self-citationHuman hypertension caused by mutations in the kidney isozyme of 11β–hydroxysteroid dehydrogenase
Mune, T., Rogerson, F. M., Nikkilä, H., Agarwal, A. K., & White, P. C. (1995) · Nature Genetics · doi:10.1038/ng0895-394 · Cited by 619
Renal Damage in Primary Aldosteronism: Results of the PAPY Study
Rossi, G. P., Bernini, G., Desideri, G., Fabris, B., Ferri, C., Giacchetti, G., Letizia, C., Maccario, M., Mannelli, M., Matterello, M.-J., et al. (2006) · Hypertension · doi:10.1161/01.hyp.0000230444.01215.6a · Cited by 470
Self-citationFardella, C. E., Mosso, L., Gómez-Sánchez, C., Cortés, P., Soto, J., Gómez, L., Pinto, M., Huete, A., Oestreicher, E., Foradori, A., et al. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.5.6596 · Cited by 463
Seccia, T. M., Fassina, A., Nussdorfer, G. G., Pessina, A. C., & Rossi, G. P. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00867 · Cited by 131
Glucocorticoid-remediable aldosteronism
Dluhy, R. G., & Lifton, R. P. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.12.6256 · Cited by 74
Cited by
Åkerström, T., Crona, J., Delgado Verdugo, A., Starker, L. F., Cupisti, K., Willenberg, H. S., Knoefel, W. T., Saeger, W., Feller, A., Ip, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041926 · Cited by 188
“After remaining a rare disease for several decades, more recent screening studies have, as Conns predicted, revealed primary aldosteronism as the most common form of secondary hypertension with prevalence of 10% or more in hypertensive patient populations [2,3,4,5,6,7].”
ResultClinical guidelines for the management of adrenal incidentaloma
Lee, J.-M., Kim, M. K., Ko, S.-H., Koh, J.-M., Kim, B.-Y., Kim, S. W., Kim, S.-K., Kim, H. J., Ryu, O.-H., Park, J., et al. (2017) · Endocrinology and Metabolism · doi:10.3803/enm.2017.32.2.200 · Cited by 147
Giordano, R., Marinazzo, E., Berardelli, R., Picu, A., Maccario, M., Ghigo, E., & Arvat, E. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0957 · Cited by 99
Ahmed, A. H., Gordon, R. D., Taylor, P. J., Ward, G., Pimenta, E., & Stowasser, M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1355 · Cited by 96
Role of Ca2+/Calmodulin-Dependent Protein Kinase Kinase in Adrenal Aldosterone Production
Nanba, K., Chen, A., Nishimoto, K., & Rainey, W. E. (2015) · Endocrinology · doi:10.1210/en.2014-1782 · Cited by 27
Metadata
- Authors
- Rossi, G. P., Pessina, A. C., & Heagerty, A. M.
- Venue
- Journal of Hypertension
- Published
- 2008-04
- Volume
- 26
- Issue
- 4
- Pages
- 613-621
- ISSN
- 0263-6352 (ISSN-L)
- OpenAlex
- W2131238552
- Cited by
- 120
- References
- 9
- FWCI
- 10.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Primary aldosteronism: an update on screening, diagnosis and treatment. https://app.cochat.ai/papers/10.1097/hjh.0b013e3282f4b3e6
- The paper
- Rossi, G. P., Pessina, A. C., & Heagerty, A. M. (2008). Primary aldosteronism: an update on screening, diagnosis and treatment. Journal of Hypertension. https://doi.org/10.1097/hjh.0b013e3282f4b3e6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.